A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Summary
This study is about TAK-500, given either alone or with pembrolizumab, in adults with select locally advanced or metastatic solid tumors. The aims of the study are: * to assess the safety profile of TAK-500 when given alone and when given with pembrolizumab. * to assess the anti-tumor effects of TAK-500, when given alone and when given with pembrolizumab, in adults with locally advanced or metastatic solid tumors. Participants may receive TAK-500 for up to 1 year. Participants may continue with their treatment if they have continuing benefit and if this is approved by their study doctor. Participants who are receiving TAK-500 either alone or with pembrolizumab will continue with their treatment until their disease progresses or until they or their study doctor decide they should stop this treatment.
Timeline
- Start
- 2022-04-14
- Primary completion
- 2025-01-06
- Completion
- 2025-01-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | TAK-500 | Unknown | 8 ug/kg | Intravenous |
| Subject | TAK-500 | Unknown | 16 ug/kg | Intravenous |
| Subject | TAK-500 | Unknown | 24 ug/kg | Intravenous |
| Subject | TAK-500 | Unknown | 40 ug/kg | Intravenous |
| Subject | TAK-500 | Unknown | 60 ug/kg | Intravenous |
| Background | Dexamethasone | Small molecule | 10 mg | Intravenous |
| Background | Tocilizumab | Monoclonal antibody | 8 mg/kg | Intravenous |